Back to News
Market Impact: 0.35
Akebia Therapeutics Reports Third Quarter 2026 Financial Results
Source: Nasdaq
Corporate EarningsCompany FundamentalsHealthcare & Biotech
Akebia Therapeutics reported third-quarter 2026 revenue of $36.9 million, down from $58.8 million in Q3 2025, a decrease of approximately 37%. The company attributed the decline primarily to lower Auryxia net product revenue, which was $20.0 million; the supplied article excerpt does not provide further results or outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
AKBA-0.45
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook